The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Investigating the safety and efficacy of re-treating CLL patients with venetoclax-based regimens
In this video, Paula Cramer, MD, University of Cologne, Cologne, Germany, shares some results from a study evaluating the safety and efficacy of re-treating chronic lymphocytic leukemia (CLL) patients with venetoclax-based regimens following relapse. Dr Cramer first explains the rationale behind this study, and then discusses the patient population enrolled. Following this, Dr Cramer highlights the results obtained, which suggest that re-treatment with venetoclax-based regimens appears to be safe and efficacious, with no increase in adverse events (AEs). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
